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Abstract  
Background: Epidermodysplasia verruciformis (EV) is a genodermatosis leading to infections 
with cutaneous HPV, persistent plane warts and a high rate of non-melanoma skin cancer 
(NMSC). Biallelic loss-of-function mutations in TMC6 and TMC8 are known to be causative. 
Objective: The aim of this study was to report EV-causing mutations in four patients with EV 
and to give an overview of all described EV patients. 
Patients and methods: We investigated four patients with classical features of EV from two 
families. All patients were affected by plane warts with typical EV histology since early 
childhood and β-HPVs were detected on their skin. One patient had recurring cutaneous 
squamous cell carcinomas (cSCC) and carcinomas in situ (Bowen type). We sequenced both 
TMC6/8 for disease-causing mutations and quantified levels of gene expression. We also 
performed a systematic literature review to discuss these patients in the context of previously 
reported cases, mutations already identified, as well as HPV types.  
Results: Three patients of one family carried a homozygous splice site mutation in TMC8 
resulting in aberrantly spliced transcripts that were not degraded. By contrast, no TMC6/8 
mutation was detected in the patient from the other family. A systematic literature review 
revealed 501 described EV patients. Around 40% of EV patients analysed for genetic 
alterations carried no mutation in TMC6/8. While β-HPVs were identified in the majority of 
cases, α-HPVs were detected in several individuals.  
Conclusion: The relatively high proportion of EV patients without mutation in TMC6/8 
indicates the existence of EV-causing mutations in additional, presently unknown gene(s). 
However, a homozygous TMC8 splice site mutation in our patients resulted in aberrant 
transcripts which cannot retain the healthy phenotype. The literature review revealed that 
HPV-5 is the most commonly identified HPV in EV patients, but HPV-3, HPV-14, and HPV-20 




Epidermodysplasia verruciformis (EV) (OMIM 226400) is a rare, autosomal recessive 
genodermatosis with unknown prevalence. EV patients develop plane wart-like lesions during 
childhood and have a high risk for early onset development of non-melanoma skin cancer 
(NMSC) on UV light exposed skin. Biallelic loss-of-function (LoF) mutations in either TMC6 or 
TMC8, also named EVER1 or EVER2, both located on chromosome 17q, are causative for 
EV1,2. Complete loss of TMC8 protein has been shown in two cases3. On the other hand, 
several patients without TMC6/8 mutation are reported. Lesions of EV patients were shown to 
harbour high copy numbers per cell of cutaneous human papilloma viruses (HPV), mainly β-
HPV, which are assumed to be carcinogenic4,5. Understanding the association between 
different HPV types and malignant transformation better would contribute to development of 
improved treatments, but very little is known about the frequency of different HPV types in EV 
patients or about differences in HPV infection between patients and the general population. In 
this study, which has been approved by the local ethics committee (EKNZ), we describe the 
clinical and genetic background of four patients with classical phenotype of EV. By reviewing 
the literature, we furthermore address the open questions regarding the total number of 
published EV patients, the proportion of families that carry deleterious mutations in TMC6/8, 
and the HPV types identified. 
 
Case 1 
A Swiss woman aged 49 was examined. Her parents were first cousins. Since early 
childhood, reddish skin lesions on the back of her hands and the extensor sides of her knees 
were visible. The lesions extended to the retroauricular area, neck, chest, arms, hands, 
knees, and lower legs (Fig. 1a-b). They showed the typical histological appearance of plane 
warts with minimal hyperkeratosis, acanthosis, as well as some cells with perinuclear halos 
and bluish staining (Fig. 1c). The patient had few persistent palmar lesions similar to palmar 
pits which were dermatoscopically consistent with plane warts (Fig. 1d). This is a very rare 
feature of EV which has been described in only three patients so far6-8. The patient developed 
multiple cutaneous squamous cell carcinomas (cSCC) and carcinomas in situ (Bowen type), 
	
mainly on her forehead and nose (Fig. 1e). After the patient provided informed consent, blood 
samples and skin biopsies were taken. The whole coding sequence of TMC6 and TMC8, as 
well as adjacent intronic regions, was sequenced as described elsewere1. Some common 
SNPs without effect on the protein sequence were detected, as well as a heterozygous SNP 
in TMC8 (rs7208422, c.917A>T, p.Asn306Ile, MAF = 0.45), but no LoF mutation was found. 
In a skin biopsy, HPV type 5 was detected by using nested PCR with primers specific for the 
L1 capsid gene and subsequent Sanger sequencing. 
 
Cases 2-4 
Three Turkish siblings aged 12, 17, and 18 years, as well as their healthy parents, who were 
second-degree cousins, were included in our study. The siblings developed plane warts 
during early childhood (Fig. 2a-b). The lesions had an appearance typical for EV and 
histopathological examination confirmed the diagnosis based on the presence of so-called 
blue cells (Fig. 2c). These three patients have not yet developed any cancerous lesions, 
probably because of their young age. Two aunts and one uncle of the patients were affected 
by EV as well. Blood samples were obtained from the siblings and their parents after they 
provided informed consent. Sanger sequencing of all coding exons, as well as adjacent 
intronic regions of TMC6 and TMC8, revealed a homozygous splice site mutation in the donor 
splice site of IVS9 of TMC8 (c.1127+1G>C) in all patients (Fig. 2d). Both parents were 
heterozygous carriers of the identified mutation. Exon-overlapping RT-PCR on mRNA from 
blood including exon 9 and 10 yielded no product in EV-affected patients, while we obtained 
the expected PCR-product in parents and all control individuals. Quantitative RT-PCR (qRT-
PCR) was performed on TMC6 exons 4-5 and 10-11, as well as on TMC8 exons 1-2, 7-8, 9-
10, and 14-15. Results were normalized by using GAPDH, TBP, and GUSB with qbase+ 
(Biogazelle, Belgium). All examined exons of TMC6, as well as exons 1-2, 7-8, and 14-15 of 
TMC8, showed stable expression in the patients, their parents and the controls. However, 
exons 9-10 of TMC8 could not be amplified in any affected child, and expression was reduced 
in heterozygous parents compared to controls (Fig. 2e). To identify the main aberrant splice 
products, RT-PCR products of TMC8 exons 6-11 were investigated by Sanger sequencing. All 
	
splice products identified in the patients lacked complete exon 9, and a subset additionally 
lacked exon 10 (Fig. 2f). The former transcript is predicted to result in a frameshift and 
premature stop codon after 30 amino acids, while the latter transcript would result in an in-
frame deletion of 88 amino acids. With the methods described above, infections with β-HPV 
(type 5 and 9) were detected in all three patients’ plane warts. 
 
Discussion 
All cases presented in this study showed the typical clinical, histopathological, and viral 
phenotype of EV. In addition to these characteristic EV features, one individual presented 
palmar warts, which constitutes a rarely described feature of EV. This patient was affected by 
diverse NMSCs, including a cSCC on the side of her nose. Since she had never developed 
plane warts in this region before, a pre-existing lesion does not seem to be a prerequisite for 
development of NMSC. Reports about the frequency of precanceroses and NMSCs in EV 
range from none10 to numerous11. Our systematic literature review summarizes cases with 
congenital EV reported to date, including the novel patients described in this study (table 1). 
Patients were excluded if they had acquired EV (onset after HIV infection or 
immunosuppression) or had a very atypical phenotype (excessive wart growth). In total, 501 
cases belonging to 347 families have been described with slightly more male patients. The 
actual number of diagnosed individuals is probably even higher since not every case is 
presumably published. For example, a clinic in Iraq observed 4-6 affected families per year, 
mostly from two areas, without reporting details12, and Japanese clinics reported 66 patients 
in a questionnaire survey13. There are no conclusive studies about the life expectancy of EV 
patients. However, under regular treatment of precanceroses and NMSCs, patients can reach 
old age11.  
 
Despite the EV-typical appearance of patient 1, we were unable to detect any LoF mutation in 
TMC6 or TMC8. This was in contrast to the second family (cases 2-4), in whom we detected 
a splice site mutation in TMC8. Nevertheless, we were able to measure regular amounts of 
aberrantly spliced TMC8 transcripts, which is consistent with a recent report of regular level of 
	
transcripts with in-frame deletions and protein expression in one patient with splice site 
mutations in TMC810. These findings exclude the mechanism of nonsense mediated decay 
(NMD), which has been reported in patients with TMC8 premature stop mutation3. In contrast 
to these cases, our patients have not developed any NMSC so far. Moreover, the other EV 
patient with splice site mutations and stable aberrant transcripts did not develop NMSC 
either10. These findings suggest that the stable transcript and evading NMSC are potentially 
correlated, which needs to be proven in further studies and a follow-up of our young patients. 
Since 2002, the TMC6 and TMC8 genes have been analysed in 32 families, but in 
approximately 40% of them (13 families), no LoF mutation could be detected. These findings 
suggest mutations of at least one more gene connected to EV. Nearly all families with either 
TMC6 or TMC8 deficiency carry a homozygous private mutation indicating consanguinity, 
which is reported in about half of all patients. 
 
HPV analyses in samples from 208 patients showed a positive result in all except one case14. 
HPV type was determined in 180 of these cases (table S1). Beta-HPV was detected in 159 
patients, α-HPV in 57 patients, and γ-HPV in one patient (Fig. 3). Most α-HPVs were detected 
along with β-HPVs. However, some α-HPV infections were reported without co-infection with 
β-HPV. These reports should be interpreted with caution. In some studies, the methods used 
had been developed to find α-HPVs, but were unable to detect β-HPVs. Other studies 
analysed only perianal samples. In several older studies, HPV-3 was detected by using 
methods relying on DNA hybridisation or restriction enzyme digestion, without amplification or 
sequencing. These methods had limited sensitivity and did not differentiate between all types 
known today. Nevertheless, a recent report has described one individual with a cutaneous 
HPV-10 (α-HPV) infection without concurrent β-HPV infection, despite a methodical search16. 
HPV-5 and HPV-8 are often mentioned as the most frequent EV-related HPV types. In 
contrast to that current opinion, our literature review shows that HPV-14 and HPV-20 have 
been reported more frequently than HPV-8, which shows the need to pay attention to HPV 
types other than 5 and 8 in future studies. In addition, EV lesions were shown to be coinfected 
with β-HPVs and polyomaviruses17. We conclude that further investigations on the effect of β-
	
HPV types and polyomaviruses on malignant transformation are necessary to better 
understand the relation of EV and HPV. 
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Figure 1: EV lesions on (a) knees and (b) neck of patient 1. (c) Haematoxylin-eosin (HE) 
stained Bowenoid lesion. Typical pale blue cytoplasm and slightly polymorphic keratinocytes 
are visible. (d) As a rare feature, the patient showed persistent palmar lesions (marked with 
blue circles). (e) cSCC developing on the nose of the patient where no previous EV lesions 







Figure 2: EV lesions on (a) chest and (b) hands of patient 2. (c) HE stained EV lesion of 
patient 4 with typical blue cytoplasm of keratinocytes and slightly enlarged and 
hyperchromatic cells mainly in stratum granulosum. (d) Sanger sequencing of TMC8 revealed 
a mutation at the donor splice site of intron 9 (TMC8 c.1127+1G>C), which was found to be 
homozygous in all three affected siblings and heterozygous in the parents. A wildtype control 
is shown. (e) Relative expression of exons 1-2 and 9-10 of TMC8 measured by qRT-PCR. 
Each symbol represents the average of one individual measured in three replicates. The grey 
horizontal bars indicate the group average. Whereas no expression could be detected for 
exon 9-10, a regular expression level is observed for exon 1-2. (f) TMC8 splice products 
identified in controls and patients. The region covered by sequencing is indicated in black. 
The splice site mutation is indicated by an arrow. In healthy controls as well as in patients, a 
splice variant with a shortened exon 10 can be found additionally to products with full length 
exon 10, corresponding to ENST00000590184.19. All identified splice products in the patients 




Figure 3: Diagram showing the number of patients by detected HPV infections. Most patients 
were solely infected by cutaneous β-HPV but some were co-infected by cutaneous or 
mucosal α-HPV. Only once γ-HPV were identified and in three samples only mucosal α-HPV 








Table 1:  
Summary of congenital EV cases reported in the literature, including the presented patients. 
All percentages were calculated respective to all patients or families for whom the information 
is available. 
Number of published cases 501 patients from 347 families 
male / female 229 (60.7%) / 148 (39.3%) patients  
consanguineous parents 65 families 
non consanguineous parents 68 families 
HPV detection positive / negative 208 / 1 patients 
HPV type determined 180 patients 
α-HPV detected   57 (31.7%) 
β-HPV detected 159 (88.3%) 
γ-HPV detected     1 (0.6%) 
TMC6 and TMC8 sequenced 32 families 
LoF mutations in TMC6   8 (25.0%) 
LoF mutations in TMC8 11 (34.4%) 






Table S1:  
Number of EV patients with different HPV-types and species15 without consideration of 
combinations in single patients. In total, HPV detection had been performed in 209 patients 
and many patients were positive for more than one HPV type. The various studies used 
different methods for HPV detection with different sensitivities and detection ranges. 
number of 
patients 
HPV type species  
78 5 β1 
41 3 α2 
36 20 β1 
32 14 β1 
31 8 β1 
28 undetermined type - 
26 17 β2 
19 25 β1 
15 24 β1 
13 9 β2 
11 38 β2 
10 19, 23 β1, β2 
8 12, 21, 36 β1, β1, β1 
7 15, 22 β2, β2 
5 47 β1 
3 2, 10 α4, α2 
2 16, 28, 49, 57, 93 α9, α2, β3, α4, β1 
1 4, 6, 11, 18, 27, 32, 34, 37, 
53, 75, 76, 92, 96, 111 
γ1, α6, α6, α7, α4, α1, α11, β2, 
α10, β3, β3, β4, β5, β2 




Number of EV 
patients 
described
additional cases in 
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